ATMA Journey Centers Secures Supply Contract With Havn Life Sciences For GMP Grade Naturally-Derived Psilocybin On The Heels Of New Section 56 Exemptions
Supply agreement provides ATMA with a legal and reliable source of psilocybin to fuel its growth and expansion as a leader in therapy, experiential therapist training and facilitator of clinical trials
ATMA Journey Centers Announces Two New Section 56 Exemptions Granted By Health Canada, Responding To Increasing Demand For Psychedelic Medicine
Patients become part of a growing movement in Canada to increase access and awareness of psychedelic-assisted therapy to help palliative patients deal with mental distress and anxiety
Canada’s First Psychedelic Training Program for Mental Health Professionals Concludes and is Deemed a Huge Success
Innovative training program provides therapists across the country with access to leading-edge training on psychedelic medicine and assisted therapy with Continuing Education Credits
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption.
Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study
Study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression.
Psilocybin Produces Substantial & Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer
Study finds that high-dose psilocybin produced large decreases in measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.